Japan Peptide Therapeutics Market

Japan Peptide Therapeutics Market Size Insights Forecasts to 2035

• The Japan Peptide Therapeutics Market Size Was Estimated at USD 3010.7 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 7.7% from 2025 to 2035
• The Japan Peptide Therapeutics Market Size is Expected to Reach USD 6809.9 Million by 2035

According to a Research Report Published by Decisions Advisors & Consulting, The Japan Peptide Therapeutics Market Size is anticipated to Reach USD 6809.9 Million by 2035, Growing at a CAGR of 7.7% from 2025 to 2035. The Japan peptide therapeutics market is driven by rising chronic disease prevalence, expanding R&D investment, favorable regulatory support, growing biologics adoption, and increasing demand for targeted and effective treatment options.

Market Overview

Peptide therapeutics involve drugs composed of amino acid chains (peptides) that mimic naturally occurring biological molecules. They are designed to target specific receptors or biological pathways with high precision, often with better safety profiles compared to traditional small-molecule drugs. The market for peptide therapeutics in Japan is projected to grow significantly, fueled by government investments, advancements in peptide drug technology, and increasing demand for personalized medicine. The focus on combining peptides with diagnostic tools and developing peptide-drug conjugates exemplifies Japan’s strategic push toward innovative, targeted treatments.

The Japan government has ramped up funding through various programs, including the cyclic innovation for clinical empowerment and public-private R&D initiatives, particularly targeting biopharmaceutical startups and university collaborations. Okinawa and Kyushu regions are also notable for their contributions to innovative peptide research, supported by government backing and academic partnerships.

Report Coverage                       

This research report categorizes the market for the Japan peptide therapeutics market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan peptide therapeutics market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan peptide therapeutics market.

Driving Factors                                                              

The peptide therapeutics markets in Japan are driven by rising demand for personalized and targeted treatments, especially for chronic diseases like diabetes and cancer, as well as an aging population needing advanced therapies. Government investment, regulatory support, and technological advancements such as AI-driven drug discovery are accelerating innovation and market growth. Companies are focusing on improving peptide efficacy and safety, while regions like Kansai and Kyushu foster biotech startups and academic collaborations, further boosting the sector’s expansion.

The rising demand for innovative peptide-based solutions that combine precise targeting and effective therapy to enhance patient outcomes. For example, in October 2024, Curium formed a partnership with PDRadiopharma Inc. to advance the clinical development and commercialization of the drug in Japan.

Restraining Factors                                         

The peptide therapeutics market in Japan is restrained by high development costs, complex manufacturing processes, regulatory challenges, limited delivery technologies, reimbursement hurdles, and competition from alternative biologics reduce adoption rates.

Market Segmentation

The Japan peptide therapeutics market share is categorized by marketing type, application and route of administration.                                

• The branded segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.                       

The Japan peptide therapeutics market is segmented by marketing type into generic, branded. Among these, the branded segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by strong physician preference for high-efficacy branded peptides, continuous product innovation, extensive clinical research, robust marketing strategies, and wider therapeutic applications that enhance adoption and premium pricing potential.

• The metabolic disorders segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

The Japan peptide therapeutics market is segmented by application into gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other. Among these, the metabolic disorders segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is due to rising incidence of diabetes and obesity, strong demand for GLP-1–based therapies, continuous product innovation, expanded clinical indications, and increasing healthcare focus on effective long-term metabolic disease management.

• The parenteral segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.                       

The Japan peptide therapeutics market is segmented by route of administration into parenteral, oral, and others. Among these, the parenteral segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by high bioavailability of injectable peptides, widespread clinical use, rapid therapeutic action, advancements in injection technologies, and strong adoption of parenteral formulations for chronic and acute conditions requiring reliable drug delivery.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan peptide therapeutics market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                      

• PeptiDream
• PeptiStar, Inc.
• Shionogi & Co., Ltd.
• Nippon Shinyaku Co., Ltd.
• Takeda Pharmaceutical Co, Ltd.
• Pfizer Inc.
• Novo Nordisk A/S
• Others

Key Target Audience                               

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, Pfizer Inc. revealed its preferred once-daily modified-release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, following results from the ongoing pharmacokinetic study.
• In July 2024, AstraZeneca acquired of Amolyt Pharma, a clinical-stage biotech firm dedicated to pioneering treatments for rare endocrine disorders. This acquisition enhances the late-stage pipeline of Alexion, a part of AstraZeneca Rare Disease, and strengthens its bone metabolism portfolio.

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Japan Peptide Therapeutics Market based on the below-mentioned segments:

Japan Peptide Therapeutics Market, By Marketing Type

• Generic
• Branded

Japan Peptide Therapeutics Market, By Application

• Gastrointestinal Disorders
• Neurological Disorders
• Metabolic Disorders
• Cancer
• Other 

Japan Peptide Therapeutics Market, By Route of Administration

• Parenteral
• Oral
• Others

FAQ’s   

Q: What is the size of the Japan peptide therapeutics market in 2024?

A: The market size was estimated at USD 3,010.7 million in 2024.

Q: What is the expected CAGR for the market from 2025 to 2035?

A: The market is expected to grow at a CAGR of 7.7% during 2025–2035.

Q: Which marketing type dominates the Japan peptide therapeutics market?

A: The branded segment accounted for the largest revenue share in 2024.

Q: Which application segment leads the market?

A: Metabolic disorders dominated in 2024, driven by demand for GLP-1 therapies and rising diabetes/obesity prevalence.

Q: What is the leading route of administration for peptide therapeutics in Japan?

A: The parenteral segment accounted for the largest revenue share due to high bioavailability and clinical adoption.

Q: Who are some key companies in the Japan peptide therapeutics market?

A: Key companies include PeptiDream, PeptiStar, Shionogi, Nippon Shinyaku, Takeda, Pfizer, and Novo Nordisk